Health Press Release – Newsletter for January 27, 2011

Reverse Liposuction “set to end World Poverty”

LONDON, January 26, 2011 – More than a third of Britons (38 per cent) have said they
would sign up for a new weight loss treatment that would see their excess fat
siphoned off – and donated to starving people in Africa and the developing
world.

The findings, from international development charity Practical
Action (www.practicalaction.org/fat-of-the-land/fat-of-the-land-video)
, … Read : Reverse Liposuction "set to end World Poverty".

Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Strong Ongoing Earnings Outlook for 2011

ABBOTT PARK, Illinois, January 26, 2011 -

– Worldwide Sales Increased 13.4 Percent -

– Fourth Quarter Ongoing EPS Growth of 10.2 Percent -

… Read more »».

Long-Term European Data Released for SUPERA(R) Stent from IDEV Technologies

Impressive Two-Year Patency Results Reported for SFA Procedures, with Zero Stent Fractures

LEIPZIG, Germany, January 26, 2011 – IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced the release of two-year European data from the prominent
Leipzig Registry, which tracks patients treated with the SUPERA wire
interwoven nitinol stent. …. Original source  : Long-Term European Data Released for SUPERA(R) Stent from IDEV Technologies.

Lebanon to Strengthen Primary Health Care

OTTAWA, January 26, 2011 – The Ministry of Public Health in Lebanon has kept primary health care as
a priority by continuing to invest in improving the quality of primary health
care in Lebanon. Starting in January 2011, Accreditation Canada International
will provide training on quality improvement and the accreditation process,
as well as help in the development …. Source  : Gaea News Network.

FDA Advisory Committee Votes Favorably on Expanding the Indication for Abbott’s Carotid Stent System to Include Patients at Standard Surgical Risk

ABBOTT PARK, Illinois, January 26, 2011 – Abbott (NYSE: ABT) today announced that the U.S. Food and Drug
Administration (FDA) Circulatory System Devices Panel of the Medical Devices
Advisory Committee voted that, for symptomatic and asymptomatic carotid
artery disease patients at standard surgical risk, there is reasonable
assurance that the benefits of the RX ACCULINK(R) Carotid Stent System
outweigh … Read more »»».